Name
Globulins
Accession Number
DBCAT000022
Description

A group of proteins that are salt-soluble and form a large fraction of BLOOD PROTEINS. There are three types of globulins, ALPHA-GLOBULINS, BETA-GLOBULINS, and GAMMA-GLOBULINS, which are distinguished from one another by their degree of electrophoretic mobility.

Drugs
DrugDrug Description
CetuximabAn endothelial growth factor receptor binding fragment used to treat colorectal cancer as well as squamous cell carcinoma of the head and neck.
Human immunoglobulin GA purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
OmalizumabA monoclonal anti-immunoglobulin E (IgE) antibody used to treat asthma, chronic idiopathic urticaria, chronic rhinosinusitis with nasal polyps, and IgE-mediated food allergy.
AdalimumabA monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
InfliximabA monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis.
TrastuzumabA monoclonal anti-human epidermal growth factor receptor 2 protein antibody used to treat HER2-positive breast, gastroesophageal, and gastric cancers.
RituximabA monoclonal anti-CD20 antibody used to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, pemphigus vulgaris, and rheumatoid arthritis.
BasiliximabA monoclonal anti-C25 antibody (interleukin-2 receptor alpha subunit) used as immunosuppressive therapy in kidney transplant patients.
MuromonabA monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients.
TositumomabA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
AlemtuzumabA monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
NatalizumabA monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis.
PalivizumabA monoclonal anti respiratory syncytial virus F protein antibody used to prevent serious sequelae caused by respiratory syncytial virus infection in pediatric patients.
BevacizumabA monoclonal anti-vascular endothelial growth factor antibody used in combination with antineoplastic agents for the treatment of many types of cancer.
EculizumabA recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
PanitumumabA recombinant humanized monoclonal antibody used to treat EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
RamucirumabAn antineoplastic agent and direct VEGFR2 (vascular endothelial growth factor receptor 2) antagonist that blocks the binding of natural VEGF ligands, which are secreted by solid tumors to promote angiogenesis and enhance tumor blood supply.
UstekinumabA targeted antibody therapy used to manage inflammatory conditions such as plaque psoriasis, psoriatic arthritis, Crohn's Disease, and ulcerative colitis.
LeronlimabA humanized monoclonal antibody being investigated
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
CanakinumabAn interleukin-1β blocker used to treat Periodic Fever Syndromes such as Cryopyrin-Associated Periodic Syndromes (CAPS) and Familial Mediterranean Fever (FMF), and also to treat active Systemic Juvenile Idiopathic Arthritis (SJIA).
IpilimumabA human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
TocilizumabAn interleukin-6 (IL-6) receptor antagonist used to treat Cytokine Release Syndrome (CRS), Systemic Juvenile Idiopathic Arthritis (sJIA), Giant Cell Arteritis (GCA), and Rheumatoid Arthritis (RA).
PertuzumabAn antineoplastic agent used in the treatment of HER2-positive metastatic breast cancer in combination with other antineoplastic agents.
CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
MepolizumabA fully-humanized monoclonal IgG1 kappa anti-IL-5 antibody used in conjunction with other therapies to treat severe asthma, eosinophilic granulomatosis with polyangiitis, and hypereosinophilic syndrome.
OfatumumabAn anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.
GolimumabA TNFα inhibitor used in the symptomatic treatment of various active inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
NivolumabA PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
DaratumumabA CD38-directed cytolytic antibody used alone or as an adjunct drug in the treatment of multiple myeloma and light chain amyloidosis.
IxekizumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
AtezolizumabA monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.
Human varicella-zoster immune globulinA solution of antibodies used for post exposure prophylaxis of varicella infections in high risk populations, as well as to reduce the severity of infections.
DurvalumabAn antineoplastic monoclonal antibody used to treat urothelial carcinoma and locally advanced, unresectable non-small cell lung cancer.
SarilumabA monoclonal antibody used to treat moderate to severe rheumatoid arthritis who have responded poorly or are intolerant of other DMARDs.
GuselkumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
RomosozumabA monoclonal antibody used to treat osteoporosis in postmenopausal women at high risk of fracture, patients who are intolerant of other treatments, or patients who have failed other treatments.
AvelumabAn anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
AnifrolumabA monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus.
OcrelizumabA CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis.
DupilumabA monoclonal antibody used to treat moderate to severe atopic dermatitis, asthma, and nasal polyps accompanied by chronic rhinosinusitis in adolescents and adults.
TralokinumabA monoclonal antibody directed against interleukin-13 which is used in the treatment of moderate-to-severe atopic dermatitis in patients requiring systemic therapy.
Polatuzumab vedotinA CD79b antibody conjugate indicated to treat different types of large B-cell lymphoma.
AducanumabA monoclonal antibody indicated in the treatment of Alzheimer's disease.
MogamulizumabA monoclonal antibody used to treat relapsed or refractory mycosis fungoides or Sézary syndrome after attempting one other therapy.
InebilizumabA humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD).
IbalizumabA CD4-specific antibody used to treat HIV infections.
AbituzumabAbituzumab has been used in trials studying the treatment of Prostate Cancer Metastatic.
Sacituzumab govitecanSacituzumab govitecan targets TROP-2-expressing cancer cells through a humanized antibody (RS7) before subsequently becoming internalized and releasing the topoisomerase I inhibitor SN-38 to induce DNA damage-mediated apoptosis.
OlokizumabA humanized anti-IL-6 IgG4κ antibody under investigation for use in autoimmune conditions including rheumatoid arthritis.
EmicizumabAn antibody against Factor IXa and Factor X used to treat hemophilia A.
TildrakizumabAn interleukin-23 antagonist used to treat moderate to severe plaque psoriasis.
FremanezumabA humanized monoclonal antibody directed against human calcitonin-gene related peptide to prevent migraines.
LanadelumabA monoclonal antibody targeted against kallikrein which is used to treat attacks of hereditary angioedema.
EmapalumabAn interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis.
RisankizumabAn interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults.
IsatuximabA chimeric monoclonal antibody targeted against surface CD38 glycoproteins for the treatment of multiple myeloma in patients who have failed previous therapies.
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia, myelodysplastic syndromes, and neoplasms.
EptinezumabA monoclonal antibody directed against CGRP infused every 3 months for the preventive treatment of migraine in adults.
GalcanezumabA calcitonin-gene related peptide antagonist used to prevent migraines and treat cluster headaches.
CemiplimabA programmed death receptor-1 blocking antibody used to treat cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer.
BrolucizumabAn anti VEGF-A monoclonal antibody indicated to treat neovascular age related macular degeneration.
Trastuzumab deruxtecanAn antibody used to treat certain types of unresectable or metastatic HER2 positive breast cancer.
MargetuximabAn Fc-engineered human/mouse chimeric IgG1κ anti-HER2 monoclonal antibody indicated for patients with HER2-positive metastatic breast cancer.
TafasitamabA CD19-directed cytolytic monoclonal antibody used in the treatment of B-cell malignancies.
TezepelumabA human monoclonal IgG2λ thymic stromal lymphopoietin (TSLP)-blocking antibody for add-on maintenance therapy in severe asthma.
EvinacumabA monoclonal antibody targeted against angiopoetin-like protein 3 (ANGPTL3) used as an adjunct with other lipid-lowering therapies for the treatment of homozygous familiar hypercholesterolemia.
TeprotumumabA fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease.
Belantamab mafodotinAn anti B-cell maturation antigen antibody conjugated to a microtubule inhibitor to treat relapsed or refractory multiple myeloma.
AmivantamabAn EGF and MET receptor targeted antibody indicated in the treatment of non-small cell lung cancer with an EGFR 20 exon insertion mutation.
PlasminogenPlasma-derived human plasminogen administered intravenously to treat type 1 plasminogen deficiency (hypoplasminogenemia).
Alpha-1-proteinase inhibitorA purified form of human alpha-1 proteinase inhibitor used to treat emphysema patients with associated alpha-1 proteinase inhibitor deficiency.
ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
Hepatitis B immune globulinAn injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection.
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
Plasma protein fraction (human)A plasma protein solution used to treat coagulation factor deficiencies, reverse anticoagulant effects, and shock from a loss of plasma fluids, and is also used in plasma exchange procedures.
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
EflapegrastimA form of recombinant human granulocyte colony stimulating factor used to induce the production of granulocytes and lower infection risk after myelosuppressive therapy.
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
RemtolumabRemtolumab is under investigation in clinical trial NCT02433340 (Phase 2, Multicenter, Open-Label Extension (OLE) Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study).
LutikizumabLutikizumab is under investigation in clinical trial NCT02087904 (A Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis).
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
Gemtuzumab ozogamicinA monoclonal anti-CD33 antibody used to treat CD33-positive acute myeloid leukemia.
Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
Ibritumomab tiuxetanA monoclonal anti-CD20 antibody used to treat B-cell non-Hodgkin's lymphoma via a conjugated radioactive isotope.
Capromab pendetideA monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
AlefaceptA recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.
EfalizumabA monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis.
Antithymocyte immunoglobulin (rabbit)A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants.
DaclizumabA monoclonal anti-CD25 antibody that blocks the interleukin-2 receptor which is used to treat relapsing forms of multiple sclerosis.
Technetium Tc-99m arcitumomabFor imaging colorectal tumors
RanibizumabA recombinant humanized monoclonal antibody and VEGF-A antagonist used for the management of macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
AbataceptA disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease.
GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
PexelizumabFor the treatment of inflammation during cardiac surgery.
AfelimomabInvestigated for use/treatment in sepsis and septicemia.
EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
OregovomabInvestigated for use/treatment in ovarian cancer.
IGN311Intended for the treatment of various forms of cancer.
AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
CR002Investigated for use/treatment in nephropathy.
RozrolimupabInvestigated for use/treatment in thrombocytopenia.
GirentuximabInvestigated for use/treatment in gall bladder cancer and renal cell carcinoma.
ObiltoxaximabA monoclonal antibody used for prophylaxis or treatment of inhalational anthrax.
XTL-001Investigated for use/treatment in hepatitis (viral, B).
Talactoferrin alfaInvestigated for use/treatment in adverse effects (chemotherapy), cancer/tumors (unspecified), diabetic foot ulcers, lung cancer, solid tumors, and ulcers.
NAV 1800Investigated for use/treatment in colorectal cancer and solid tumors.
BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
AMG 108Investigated for use/treatment in osteoarthritis and rheumatoid arthritis.
IratumumabInvestigated for use/treatment in lymphoma (unspecified).
EnokizumabInvestigated for use/treatment in asthma.
FarletuzumabInvestigated for use/treatment in ovarian cancer.
VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
Trastuzumab emtansineAn antineoplastic agent and antibody-drug conjugate used to treat HER2-overexpressing breast cancer.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
TNX-901Investigated for use/treatment in allergic reaction.
Inotuzumab ozogamicinAn antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL).
RI 624Investigated for use/treatment in pain (acute or chronic).
StamulumabInvestigated for use/treatment in muscular dystrophy.
CT-011Investigated for use/treatment in cancer/tumors (unspecified).
PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
MK-4721Investigated for use/treatment in prostate cancer.
Glembatumumab vedotinInvestigated for use/treatment in melanoma.
OlaratumabA platelet-derived growth factor receptor alpha blocking antibody used with doxorubicin to treat patients with certain types of soft tissue sarcoma (STS).
IPH 2101Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
TB-402Investigated for use/treatment in atrial fibrillation and thrombosis.
IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
EldelumabInvestigated for use/treatment in ulcerative colitis.
LumiliximabInvestigated for use/treatment in asthma and leukemia (lymphoid).
NimotuzumabAn EGFR-targeting monoclonal antibody used in the treatment of squamous cell carcinomas of the head and neck and glioblastomas.
ClenoliximabInvestigated for use/treatment in rheumatoid arthritis.
OtilimabInvestigated for use/treatment in inflammatory disorders (unspecified).
BIIB015Investigated for use/treatment in solid tumors.
SonepcizumabInvestigated for use/treatment in solid tumors.
MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
ElotuzumabAn antineoplastic agent and SLAMF7-directed immunostimulatory antibody used for the treatment of refractory multiple myeloma in combination with other antineoplastic agents.
AVE9633Investigated for use/treatment in leukemia (myeloid).
CarotuximabInvestigated for use/treatment in solid tumors.
XmAb 2513Investigated for use/treatment in lymphoma (unspecified) and lymphoma (non-hodgkin's).
Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
SibrotuzumabInvestigated for use/treatment in cancer/tumors (unspecified), colorectal cancer, and lung cancer.
AtibuclimabInvestigated for use/treatment in sepsis and septicemia and pneumonia.
BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
LerdelimumabInvestigated for use/treatment in glaucoma and cataracts.
LexatumumabInvestigated for use/treatment in cancer/tumors (unspecified).
ReslizumabAn IL-5 antagonist used as an add-on maintenance treatment of patients with severe eosinophilic asthma in adults.
TeplizumabA CD3-directed monoclonal antibody indicated to delay the onset of Stage 3 type 1 diabetes in patients with Stage 2 type 1 diabetes.
DenosumabA RANK ligand (RANKL) inhibitor used for the management of osteoporosis in patients at high risk for bone fractures.
VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
BelataceptA selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant.
Brentuximab vedotinA CD30-directed antibody-drug conjugate used to treat various types of lymphoma.
BelimumabA B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy.
RaxibacumabA monoclonal antibody used in conjunction with an antibacterial regimen to treat patients with inhalational anthrax caused by Bacillus anthracis and for prophylaxis of inhalational anthrax when appropriate.
ObinutuzumabAn antineoplastic CD20 antibody used to treat untreated chronic lymphocytic leukemia in combination with chlorambucil.
SecukinumabAn immunomodulating agent and interleukin antagonist used to manage plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, along with other joint inflammatory disorders.
VedolizumabAn integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults.
SiltuximabAn interleukin antagonist used to treat multicentric Castleman's disease (MCD) in patients who are HIV and HHV-8 negative.
PembrolizumabA PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.
BlinatumomabAn antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD).
DinutuximabAn immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Asfotase alfaAn enzyme replacement therapy used for the treatment of perinatal/infantile and juvenile onset hypophosphatasia (HPP).
IdarucizumabAn antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran.
AlirocumabA PCSK9 inhibitor used as an adjunct to manage heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients who require additional lowering of LDL-cholesterol (LDL-C).
EvolocumabA PCSK9 (proprotein convertase subtilisin kexin type 9) inhibitor antibody used as an adjunct to LDL cholesterol reducing therapies, aiding in the prevention of cardiovascular events and cardiovascular revascularization procedures.
Antilymphocyte immunoglobulin (horse)A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients.
Technetium Tc-99m nofetumomab merpentanTc-99m nm is one of the technetium-labeled antibodies and it is indicated for the detection of small-cell lung cancer. The small cell lung cancer is a syndrome characterized by the...
NecitumumabA monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
RavulizumabA monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.
Antithrombin III humanAn alpha-2-glycoprotein used to prevent thromboembolisms in patients with hereditary antithrombin III deficiency.
ConatumumabConatumumab has been used in trials studying the treatment of Sarcoma, Lymphoma, Oncology, Colon Cancer, and Rectal Cancer, among others.
TabalumabTabalumab has been used in trials studying the treatment of Autoimmune Disease, Rheumatoid Arthritis, Kidney Failure, Chronic, Connective Tissue Disease, and Systemic Lupus Erythematosus, among others.
FiclatuzumabFiclatuzumab has been used in trials studying the treatment of Acute Myeloid Leukemia, Non-small Cell Lung Cancer, Mullerian Mixed Tumor of Ovary, Relapsed Acute Myeloid Leukemia, and Refractory Acute Myeloid...
FigitumumabFigitumumab has been used in trials studying the treatment of Sarcoma, Solid Tumor, Breast Cancer, Lung Neoplasms, and Advanced Cancer, among others.
BapineuzumabBapineuzumab has been investigated for the treatment of Alzheimer's Disease.
Depatuxizumab mafodotinNo approved indication.
OnartuzumabOnartuzumab has been used in trials studying the treatment of Neoplasms, Lung Cancer, Glioblastoma, Gastric Cancer, and Colorectal Cancer, among others.
SolanezumabSolanezumab is under investigation for the treatment of Dementia, Alzheimers Disease, and Alzheimers Disease, Familial.
TremelimumabAn anti-CTLA-4 antibody used to treat unresectable hepatocellular carcinoma in combination with durvalumab.
BrodalumabA monoclonal antibody used to treat moderate to severe plaque psoriasis.
SirukumabSirukumab has been used in trials studying the treatment and basic science of Giant Cell Arteritis and Arthritis, Rheumatoid.
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
DalotuzumabDalotuzumab has been investigated for the treatment of Breast Cancer, Non Small Cell Lung Cancer, and Metastatic Colorectal Cancer.
EmibetuzumabEmibetuzumab has been used in trials studying the treatment of Advanced Cancer, Renal Cell Carcinoma, Hepatocellular Cancer, Gastric Adenocarcinoma, and Non-Small Cell Lung Cancer, among others.
UblituximabA low-fucose CD20-targeted monoclonal antibody used in the treatment of relapsing forms of multiple sclerosis.
SeribantumabSeribantumab has been used in trials studying the treatment of NSCLC, Heregulin, Adenocarcinoma, Colorectal Cancer, and Solid Tumor Cancers, among others.
LandogrozumabLandogrozumab has been used in trials studying the treatment of Advanced Cancer, Muscular Atrophy, and Pancreatic Cancer.
Vadastuximab talirineVadastuximab Talirine has been used in trials studying the treatment of Acute myeloid leukemia, Myelodysplastic Syndrome, Acute Myelogenous Leukemia, and Acute Promyelocytic Leukemia.
LebrikizumabAn IgG4 monoclonal antibody against IL-13 used to treat moderate-to-severe atopic dermatitis in adults and adolescents.
TesidolumabTesidolumab has been used in trials studying the treatment of Geographic Atrophy, Non-infectious Panuveitis, Exudative Macular Degeneration, Non-infectious Posterior Uveitis, and Age-related Macular Degeneration, among others.
VarlilumabVarlilumab has been used in trials studying the treatment of MELANOMA, Skin Ulcer, Burkett's Lymphoma, Mantle cell lymphoma, and Any T-cell Malignancy, among others.
CrenezumabCrenezumab has been used in trials studying the treatment of Alzheimer's Disease.
RilotumumabRilotumumab has been investigated for the treatment of Cancer, Lung Cancer, Solid Tumors, Gastric Cancer, and Prostate Cancer, among others.
UlocuplumabUlocuplumab is under investigation in Solid Tumor.
BenralizumabA monoclonal antibody used to treat severe eosinophilic asthma.
GantenerumabA fully human IgG1κ monoclonal antibody with specificity for amyloid-beta oligomers and fibrils under investigation for the treatment of Alzheimer's disease.
VisilizumabVisilizumab has been investigated for the treatment of Ulcerative Colitis.
UrelumabUrelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. Urelumab is a fully human antibody...
Lorvotuzumab mertansineLorvotuzumab mertansine has been used in trials studying the treatment of SCLC, Leukemia, Ovarian Cancer, Multiple Myeloma, and Merkel Cell Carcinoma, among others.
PatritumabPatritumab has been used in trials studying the treatment of LUNG CANCER, Solid Tumors, Neoplasms by Site, Head and Neck Neoplasms, and Non-small Cell Lung Cancer, among others.
FulranumabFulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
TarextumabTarextumab has been used in trials studying the treatment of Solid Tumors, Stage IV Pancreatic Cancer, and Stage IV Small Cell Lung Cancer.
GevokizumabGevokizumab has been used in trials studying the treatment of Acne Vulgaris, Osteoarthritis, Behcet's Uveitis, Pyoderma Gangrenosum, and Behcet's Disease Uveitis, among others. Gevokizumab acts as a modulator of cytokine...
DuligotuzumabDuligotuzumab has been used in trials studying the treatment of Neoplasms, Colorectal Cancer, Head and Neck Cancer, and Epithelial Tumors, Malignant.
SimtuzumabSimtuzumab has been used in trials studying the treatment and basic science of Myelofibrosis, Pancreatic Cancer, Colorectal Cancer, and Idiopathic Pulmonary Fibrosis.
FasinumabA monoclonal antibody targeting nerve growth factor which is under investigation for the treatment of chronic cancer and non-cancer pain.
EtrolizumabA humanized IgG1κ anti-β7 integrin subunit monoclonal antibody under investigation for use in ulcerative colitis and Crohn's disease.
ZalutumumabZalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR). Zalutumumab has been investigated for the treatment of Squamous Cell...
GanitumabGanitumab has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, Breast Cancer, Breast Tumors, and Breast Neoplasms, among others.
EtaracizumabEtaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.
Tetulomab tetraxetan Lu-177Betalutin has been used in trials studying the treatment of Non-Hodgkin Lymphoma and Relapsed, Diffuse Large B-cell Lymphoma.
InclacumabInclacumab has been used in trials studying the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease, Graft Occlusion, Vascular.
CixutumumabCixutumumab has been used in trials studying the treatment of Lung Cancer, Malignant Neoplasm, Leukemia, Mast-Cell, Non-Small-Cell Lung Carcinoma, and Adenocarcinoma of the Prostate. Cixutumumab is a highly specific recombinant...
AscrinvacumabAscrinvacumab has been used in trials studying the treatment and basic science of Neoplasms, Advanced Solid Tumors, Carcinoma, Hepatocellular, and Malignant Pleural Mesothelioma.
AnrukinzumabAnrukinzumab has been used in trials studying the diagnostic of Asthma.
GS-5745GS-5745 has been used in trials studying the treatment of Tumors, Breast Cancer, Crohn's Disease, Colorectal Cancer, and Pancreatic Cancer, among others.
VanucizumabVanucizumab has been used in trials studying the treatment of ColoRectal Cancer and Advanced/Metastatic Solid Tumors.
Labetuzumab govitecanLabetuzumab govitecan has been used in trials studying the treatment of Colon Cancer, Rectal Cancer, and Metastatic Colorectal Cancer.
TanezumabTanezumab has been investigated for the treatment of Osteoarthritis, Knee and Neuralgia, Postherpetic.
EnsituximabEnsituximab has been used in trials studying the treatment of Pancreatic Cancer, Adult, Metastatic Colorectal Cancer, and Metastatic Pancreatic Cancer.
FezakinumabFezakinumab has been used in trials studying the treatment of Atopic Dermatitis and Rheumatoid Arthritis.
FletikumabFletikumab is under investigation in clinical trial NCT01038674 (Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid Arthritis).
DusigitumabDusigitumab has been used in trials studying the treatment of Cancer, Advanced Solid Malignancies, Unresectable or Metastatic Hepatocellular Carcinoma (HCC), and Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer.
FresolimumabFresolimumab has been used in trials studying the treatment of Primary Brain Tumors, Metastatic Breast Cancer, Diffuse Systemic Sclerosis, Pleural Malignant Mesothelioma, and Primary Focal Segmental Glomerulosclerosis.
Indusatumab vedotinIndusatumab vedotin has been used in trials studying the treatment of Pancreatic Adenocarcinoma, Adenocarcinoma of the Stomach, Recurrent Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, and Advanced Gastrointestinal Carcinoma, among others.
BococizumabBococizumab has been used in trials studying the treatment and prevention of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, and Heterozygous Familial Hypercholesterolemia.
Mirvetuximab soravtansineA folate receptor alpha-directed antibody and microtubule inhibitor conjugate used to treat folate receptor alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
PlozalizumabPlozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including...
MavrilimumabMavrilimumab has been investigated for the treatment of Rheumatoid Arthritis.
BlosozumabBlosozumab has been used in trials studying the basic science and treatment of Osteoporosis and Osteoporosis, Postmenopausal.
BimagrumabBimagrumab has been used in trials studying the treatment and supportive care of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM), among others.
DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
TovetumabTovetumab has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Advanced Solid Malignancies.
NavicixizumabNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
SamalizumabSamalizumab has been used in trials studying the treatment of Multiple Myeloma and B-cell Chronic Lymphocytic Leukemia.
LumretuzumabLumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
Moxetumomab pasudotoxA CD22-specific antibody conjugated to a truncated exotoxin used to treat relapsed or refractory hairy cell leukemia in patients who have already been treated with a purine nucleoside analog and one other treatment.
IntetumumabIntetumumab has been used in trials studying the treatment of Melanoma.
CarlumabCarlumab has been used in trials studying the treatment of Cancer and Prostate Cancer.
FirategrastFirategrast has been used in trials studying the treatment of Multiple Sclerosis.
DemcizumabDemcizumab is under investigation for the treatment of Nonsquamous Nonsmall Cell Neoplasm of Lung.
SifalimumabSifalimumab is a fully human monoclonal antibody targeting interferon-alpha. The levels of interferon-alpha are elevated in many patients with active systemic lupus erythematosus (SLE, or lupus) and other autoimmune disorders,...
EcromeximabEcromeximab has been used in trials studying the treatment of Cutaneous Melanoma and Metastatic Melanoma.
Naptumomab estafenatoxNaptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.
CrotedumabCrotedumab has been used in trials studying the treatment of Diabetes Mellitus, Type 2.
ConcizumabConcizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
MonalizumabMonalizumab has been used in trials studying the treatment of Gynecologic Cancer, Chronic Lymphocytic Leukemia, and Squamous Cell Carcinoma of the Oral Cavity.
DepatuxizumabDepatuxizumab has been used in trials studying the treatment and diagnostic of Adenocarcinoma and Advanced Solid Tumors.
RontalizumabRontalizumab has been used in trials studying the treatment of Systemic Lupus Erythematosus.
AmatuximabAmatuximab has been used in trials studying the treatment and basic science of Mesothelioma, Ovarian Cancer, Ovarian Neoplasms, Pancreatic Cancer, and Mesothelioma, Malignant, among others.
ClazakizumabClazakizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
OzanezumabOzanezumab has been used in trials studying the treatment of Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Multiple Sclerosis, Relapsing-Remitting.
BimekizumabAn anti-IL-17A, IL-17F, and IL-17AF monoclonal antibody used in the treatment plaque psoriasis.
MilatuzumabMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
RobatumumabRobatumumab has been used in trials studying the treatment of Osteosarcoma, Sarcoma, Ewing's, and Peripheral Neuroectodermal Tumor.
Enfortumab vedotinAn antibody-drug conjugate comprised of a fully human monoclonal antibody and microtubule-disrupting chemotherapeutic agent used in the treatment of advanced or metastatic urothelial cancer.
Rovalpituzumab tesirineRovalpituzumab Tesirine has been used in trials studying the treatment of GLIOBLASTOMA, Malignant Melanoma, Other Solid Tumors, Small Cell Lung Cancer, and Medullary Thyroid Cancer, among others.
NamilumabNamilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.
RacotumomabRacotumomab has been used in trials studying the treatment of Glioma, Wilm's Tumor, Neuroblastoma, Retinoblastoma, and Ewing's Sarcoma.
TregalizumabTregalizumab has been used in trials studying the treatment of Rheumatoid Arthritis.
BezlotoxumabA monoclonal antibody used to reduce the recurrence of Clostridium difficile infections.
EdrecolomabNot Annotated
NebacumabNot Annotated
Human cytomegalovirus immune globulinA solution of immune globulin G against cytomegalovirus used to prevent transmission of cytomegalovirus after organ transplants.
SulesomabMarket product is Tc99m-labeled murine antibody fragment for nuclear imaging of activated granulocytes.
BesilesomabA monoclonal antibody bound to technetium-99 used to find infection and inflammation in patients with suspected osteomyelitis.
BurosumabA fibroblast growth factor 23 blocking antibody used to treat X-linked hypophosphatemia.
ErenumabA calcitonin-gene related peptide antagonist used to prevent migraines.
FanolesomabAn anti-SSEA-1 monoclonal antibody used for imaging of the appendix and to diagnose appendicitis.
LecanemabAn amyloid beta-targeting antibody used to treat Alzheimer’s Disease in patients with mild cognitive impairment or mild dementia with a known amyloid beta pathology.
CamrelizumabCamrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
SetrusumabSetrusumab is under investigation in clinical trial NCT01406548 (Safety and Efficacy of Multiple Dosing Regimens of BPS804 in Post Menopausal Women With Low Bone Mineral Density).
VofatamabVofatamab is under investigation in clinical trial NCT02401542 (Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma).
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Anetumab ravtansineAnetumab ravtansine is under investigation in clinical trial NCT03455556 (Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer).
OsocimabOsocimab is under investigation in clinical trial NCT03276143 (Factor XIa inhibition for the prevention of venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty).
IcrucumabIcrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
CodrituzumabCodrituzumab is under investigation in clinical trial NCT01507168 (A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma).
XentuzumabXentuzumab is under investigation in clinical trial NCT02191891 (Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)).
LintuzumabLintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
ImgatuzumabImgatuzumab is under investigation in clinical trial NCT01326000 (A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With...
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
SpartalizumabSpartalizumab is under investigation in clinical trial NCT02605967 (Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma).
ParsatuzumabParsatuzumab is under investigation in clinical trial NCT01366131 (Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous...
EmactuzumabEmactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).
Bevacizumab zirconium Zr-89Bevacizumab zirconium Zr-89 is under investigation in clinical trial NCT01338090 (89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors).
RefanezumabRefanezumab is under investigation in clinical trial NCT00833989 (Safety Escalating Repeat IV, in Stroke Patients).
MirikizumabAn anti-IL-23 monoclonal antibody used as a second-line therapy for moderate-to-severe active ulcerative colitis.
RozanolixizumabA humanized monoclonal antibody targeting the human neonatal Fc receptor (FcRn) used to treat generalized myasthenia gravis.
TislelizumabAn IgG4 variant monoclonal antibody against PD-1 indicated for the treatment of unresectable, locally advanced or metastatic esophageal squamous cell carcinoma
BermekimabBermekimab is under investigation in clinical trial NCT01384630 (Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis).
PamrevlumabPamrevlumab is under investigation in clinical trial NCT00913393 (Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy).
SelicrelumabSelicrelumab is under investigation in clinical trial NCT01008527 (Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100).
OpicinumabOpicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
SutimlimabA monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease.
PateclizumabPateclizumab is under investigation in clinical trial NCT01225393 (A Study to Evaluate the Efficacy and Safety of MLTA3698A in Combination With a Disease-Modifying Anti-Rheumatic Drug (DMARD) Compared With Adalimumab in...
GremubamabGremubamab is under investigation in clinical trial NCT02255760 (Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults).
ApomabApomab is under investigation in clinical trial NCT00851136 (A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and...
ToripalimabA PD-1 blocking monoclonal antibody used for the treatment of metastatic and recurrent nasopharyngeal carcinomas.
AbrilumabAbrilumab is under investigation in clinical trial NCT01290042 (Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181.).
DomagrozumabDomagrozumab is under investigation in clinical trial NCT01616277 (A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects).
FrovocimabFrovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
TigatuzumabTigatuzumab is under investigation in clinical trial NCT00991796 (CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)).
Telisotuzumab vedotinTelisotuzumab vedotin is under investigation in clinical trial NCT02099058 (A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Subjects With Advanced Solid Tumors.).
UtomilumabUtomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
ZolbetuximabZolbetuximab is under investigation in clinical trial NCT01630083 (Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer).
PonezumabPonezumab is under investigation in clinical trial NCT00607308 (A Phase I, Single Dose Study Of PF-04360365 In Japanese Patients With Mild To Moderate Alzheimer's Disease).
LenzilumabLenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
FibronectinFibronectin is under investigation in clinical trial NCT01812239 (Vaginal Progesterone in Twins With Short Cervix).
AsunerceptAsunercept is under investigation in clinical trial NCT02853565 (A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme).
SuvratoxumabSuvratoxumab is under investigation in clinical trial NCT02296320 (Study of the Efficacy and Safety of MEDI4893).
MitazalimabMitazalimab is under investigation in clinical trial NCT02379741 (ADC-1013 First-in-Human Study).
NemolizumabNemolizumab is under investigation in clinical trial NCT03921411 (A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Subjects With Atopic Dermatitis (AD)).
BleselumabBleselumab is under investigation in clinical trial NCT02921789 (Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant...
IscalimabIscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
FutuximabFutuximab is under investigation in clinical trial NCT01955473 (Japanese Phase 1 Trial of Sym004 in Solid Tumors).
Efgartigimod alfaA neonatal Fc receptor blocker used to treat generalized myasthenia gravis in patients who are AChR-antibody positive.
CrizanlizumabA monoclonal antibody that targets selectin to reduce the frequency of vasooclusive crises in patients with sickle cell disease.
EdratideEdratide is under investigation in clinical trial NCT00203151 (A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus).
GedivumabGedivumab is under investigation in clinical trial NCT01877785 (A Study of MHAA4549A to Assess Safety And Pharmacokinetics in Healthy Volunteers).
GimsilumabGimsilumab is under investigation in clinical trial NCT01357759 (Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects).
OntamalimabOntamalimab is under investigation in clinical trial NCT03627091 (Efficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)).
OrilanolimabOrilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).
Valanafusp alfaValanafusp alfa is under investigation in clinical trial NCT03071341 (Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS I).
Sofituzumab vedotinSofituzumab vedotin is under investigation in clinical trial NCT01335958 (Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer).
IstiratumabIstiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
GosuranemabGosuranemab is under investigation in clinical trial NCT02460094 (Multiple Ascending Dose Study of Intravenously Administered BMS-986168 (BIIB092) in Patients With Progressive Supranuclear Palsy).
PidilizumabPidilizumab is under investigation in clinical trial NCT01952769 (Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma).
GMA-161GMA-161 is under investigation in clinical trial NCT00244257 (Safety Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura (ITP)).
Lifastuzumab vedotinLifastuzumab vedotin is under investigation in clinical trial NCT01363947 (Safety and Pharmacokinetics of Escalating Doses of DNIB0600A in Participants With Non-Small Cell Lung Cancer (NSCLC) and Platinum Resistant Ovarian Cancer).
Ladiratuzumab vedotinLadiratuzumab vedotin is under investigation in clinical trial NCT01969643 (A Safety Study of SGN-LIV1A in Breast Cancer Patients).
TomaralimabTomaralimab is under investigation in clinical trial NCT01794663 (Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function).
VesencumabVesencumab is under investigation in clinical trial NCT00747734 (A Study of MNRP1685A in Patients With Locally Advanced or Metastatic Solid Tumors).
ElgemtumabElgemtumab is under investigation in clinical trial NCT02167854 (Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer).
Pinatuzumab vedotinPinatuzumab vedotin is under investigation in clinical trial NCT01691898 (A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With...
Lulizumab pegolLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Lorukafusp alfaLorukafusp alfa is under investigation in clinical trial NCT01334515 (Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma).
Naratuximab emtansineNaratuximab emtansine is under investigation in clinical trial NCT01534715 (IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia).
ZenocutuzumabZenocutuzumab is under investigation in clinical trial NCT03321981 (MCLA-128 With Trastuzumab/chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer).
SpesolimabAn interleukin-36 receptor antagonist used to treat generalized pustular psoriasis flares in adults.
DostarlimabAn anti-PD-1 monoclonal antibody used in the treatment of mismatch repair deficient endometrial cancers and solid tumours with no alternative treatment options.
InolimomabInolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry...
TemelimabTemelimab is under investigation in clinical trial NCT02782858 (Clinical Trial Assessing the HERV-W Env Antagonist Gnbac1 for Efficacy in MS).
Anti-SARS-CoV-2 REGN-COV2Anti-SARS-COV-2 REGN-COV2 is a combination of novel antibodies designed by Regeneron for both the prevention and treatment of SARS-COV-2, the virus that causes COVID-19. This drug is a combination of...
TheralizumabTheralizumab is a humanized anti-CD28 monoclonal antibody designed for treating autoimmune diseases and cancer. After the first human trial, it was withdrawn due to severe toxicity (likely due to lymphopenia...
BamlanivimabA neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19.
SatralizumabA subcutaneously injected anti-IL-6 receptor monoclonal antibody for the treatment of neuromyelitis optica spectrum disorder (NMOSD).
SintilimabNot Annotated
EnvafolimabNot Annotated
AZD7442AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the...
PentaglobinPentaglobin, also known as IgM-enriched immunoglobulin, falls under a group of polyclonal immunoglobulin preparations. It is comprised of immunoglobulin G (IgG) (https://www.drugbank.ca/drugs/DB00028) and immunoglobulin A (IgA) while also being enriched...
XAV-19XAV-19 is an intravenous antibody-based treatment targeted towards SARS-CoV-2 and other coronaviruses[L16553,L16558]. The therapy concept is based on COVID-19 convalescent plasma. However, rather than using human plasma, XAV-19 is a...
EtesevimabEtesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral...
AtoltivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
MaftivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
OdesivimabPart of a product containing three monoclonal IgG1κ antibodies directed against the GP1,2 glycoprotein of Zaire ebolavirus. Together, these three antibodies act to neutralize viral particles and to recruit immune effectors for the destruction of both viral particles and infected cells.
ImdevimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
CasirivimabPart of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19.
NaxitamabA GD2-targeted IgG1 monoclonal antibody for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
AbagovomabAbagovomab is under investigation in clinical trial NCT00418574 (Efficacy Multicentre Trial of Immunotherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients).
BemarituzumabBemarituzumab is under investigation in clinical trial NCT03694522 (A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (Mfolfox6) in Gastric/gastroesophageal Junction Cancer (FIGHT)).
Dapirolizumab pegolDapirolizumab pegol is under investigation in clinical trial NCT02804763 (A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus).
EfungumabEfungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).
ForalumabForalumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).
GlenzocimabNot Annotated
GontivimabGontivimab is under investigation in clinical trial NCT03468829 (Efficacy and Safety of ALX-0171 in Adult Hematopoietic Stem Cell Transplant (HSCT) Recipients Who Present With Respiratory Syncytial Virus (RSV) Infection).
Indatuximab ravtansineIndatuximab ravtansine is under investigation in clinical trial NCT01001442 (Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma).
ItepekimabItepekimab is under investigation in clinical trial NCT03546907 (Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of SAR440340 (Anti-il-33 Mab) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)).
ItolizumabItolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
Loncastuximab tesirineAn antibody-drug conjugate used for the treatment of relapsed and refractory B-cell lymphomas.
MagrolimabMagrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
NirsevimabA long-acting monoclonal antibody indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.
OlinvacimabOlinvacimab is under investigation in clinical trial NCT03033524 (Trial to Evaluate the Safety of Ttac-0001(tanibirumab) in Recurrent Glioblastoma).
OntuxizumabOntuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1). It is under investigation in clinical trial NCT01574716 (Sarcoma Study of Morab-004 Utilization: Research and...
OtlertuzumabOtlertuzumab is under investigation in clinical trial NCT01188681 (Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia).
Trastuzumab duocarmazineTrastuzumab duocarmazine is under investigation in clinical trial NCT03262935 (SYD985 vs. Physician's Choice in Participants With Her2-positive Locally Advanced or Metastatic Breast Cancer).
SotrovimabA monoclonal antibody for the treatment of mild-to-moderate COVID-19 in patients at increased risk for death or hospitalization.
Anti-SARS-CoV-2 immunoglobulinHyperimmune immunoglobulin to SARS-CoV-2 (hIVIG) is obtained from the plasma of patients who recover from COVID-19 and develop neutralizing antibodies. Anti-coronavirus immunoglobulin is derived from COVID-19 convalescent plasma(https://go.drugbank.com/drugs/DB15692) but contains...
GlofitamabA bispecific monoclonal antibody directed against CD20 and CD3 which is used for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
FelzartamabFelzartamab is under investigation in clinical trial NCT04145440 (Trial to Assess Safety and Efficacy of MOR202 in Anti-pla2r + Membranous Nephropathy (Amn)).
ActoxumabActoxumab is under investigation in clinical trial NCT01241552 (A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)).
ToralizumabToralizumab is under investigation in clinical trial NCT03605927 (CD40-L Blockade for Prevention of Acute Graft-versus-host Disease).
AnsuvimabA fully human monoclonal IgG1 antibody directed against the GP1,2 surface protein of Zaire ebolavirus that is an effective treatment for Ebola virus disease.
AstegolimabAstegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).
LevilimabLevilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).
AxatilimabAxatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
ZansecimabZansecimab is under investigation in clinical trial NCT04342897 (A Study of LY3127804 in Participants With COVID-19).
AvdoralimabAvdoralimab is under investigation in clinical trial NCT04333914 (Prospective Study in Patients With Advanced or Metastatic Cancer and Sars-cov-2 Infection).
CilgavimabAn extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
TixagevimabAn extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.
RegdanvimabA monoclonal antibody targeted against the SARS-CoV-2 spike protein used to treat patients with COVID-19 who are at risk of progressing to severe COVID-19.
BirtamimabBirtamimab is under investigation in clinical trial NCT02312206 (The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis).
VilobelimabAn antibody directed against anti-human complement factor 5a is used to treat COVID-19 in adults for emergency use.
NarsoplimabAn anti-MASP-2 antibody currently being investigated for use in transplant-associated thrombotic microangiopathies and IgA nephropathy.
VolagidemabVolagidemab is under investigation in clinical trial NCT03117998 (Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus).
MeplazumabMeplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.
LactoferrinLactoferrin is under investigation in clinical trial NCT03748043 (The Effectiveness of Lactoferrin in Treatment of Iron Deficiency Anemia in Children With Chronic Tonsillitis).
OrdesekimabOrdesekimab is under investigation in clinical trial NCT02633020 (Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease).
BentracimabBentracimab is under investigation in clinical trial NCT04286438 (Bentracimab (PB2452) in Ticagrelor-treated Patients With Uncontrolled Major or Life-threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure).
IanalumabIanalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
BudigalimabBudigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV...
AbelacimabAbelacimab is under investigation in clinical trial NCT04755283 (Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation).
LirentelimabLirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
EnibarcimabEnibarcimab is under investigation in clinical trial NCT03989531 (Adrecizumab in Cardiogenic Shock).
Tisotumab vedotinA tissue factor-directed antibody drug conjugate that is used to treat adults with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
BebtelovimabA human IgG1κ monoclonal antibody targeted against the spike protein of SARS-CoV-2 which is used in the treatment of mild-to-moderate COVID-19.
PriliximabNot Annotated
TOL-101Not Annotated
TilavonemabNot Annotated
Omburtamab I-131Not Annotated
ArcitumomabNot Annotated
Cantuzumab mertansineNot Annotated
MDX-210Not Annotated
EluvixtamabNot Annotated
BI-836826Not Annotated
CibisatamabNot Annotated
OcaratuzumabOcaratuzumab is a humanized monoclonal antibody directed against CD20. It is being investigated for cancers and autoimmune disorders.
ZanolimumabZanolimumab is a fully human monoclonal antibody directed against CD4.
Tusamitamab ravtansineTusamitamab ravtansine is an antibody-drug conjugate that targets carcinoembryonic antigen-related cell adhesion molecule-5 (CEACAM5).
ZimberelimabNot Annotated
AGS-16C3FAGS 16C3F is an intravenously administered, anti-ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) antibody-drug conjugate. AGS-16C3F is under investigation in clinical trial NCT02639182 (A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell...
AndecaliximabAndecaliximab is a monoclonal antibody directed against matrix metallopeptidase 9 (MMP9). Andecaliximab is under investigation in clinical trial NCT03631836 (Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase...
Evorpaceptevorpacept is under investigation in clinical trial NCT04755244 (A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)).
LirilumabLirilumab has been used in trials studying the treatment of Leukemia, CANCER,NOS, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia, among others.
Human vaccinia virus immune globulinA purified gamma globulin used to treat vaccinia infections where skin is compromised, or infections of the eyes, mouth, or other areas where vaccinia infections present a special hazard.
RelatlimabA monoclonal antibody targeted against LAG-3 which is used in combination with nivolumab for the treatment of unresectable or metastatic melanoma.
CabiralizumabCabiralizumab is under investigation in clinical trial NCT03502330 (APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma).
DezamizumabDezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).
PepinemabPepinemab is under investigation in clinical trial NCT03769155 (VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma).
ElezanumabElezanumab is under investigation in clinical trial NCT03737812 (A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis).
FaricimabAn IgG1-derived bispecific antibody against VEGF-A and Ang-2 for the treatment of age-related macular degeneration and diabetic macular edema.
ZanidatamabAccording to Zymeworks, "ZW25 is a bispecific antibody that can simultaneously bind two non-overlapping epitopes, known as biparatopic binding, of HER2 resulting in dual HER2 signal blockade, increased binding and...
BalstilimabNot Annotated
ApitegromabApitegromab is under investigation in clinical trial NCT03921528 (An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy).
BatoclimabBatoclimab is under investigation in clinical trial NCT04428255 (A Clinical Study on the Efficacy and Safety of HBM9161 in Patients With ITP).
SabatolimabSabatolimab is under investigation in clinical trial NCT03946670 (A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).).
BexmarilimabBexmarilimab is under investigation in clinical trial NCT03733990 (A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients).
SotigalimabSotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
SugemalimabSugemalimab is a fully human, full-length IgG4 monoclonal anti-PD-L1 antibody discovered by CStone Pharmaceuticals and being investigated against relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (R/R ENKTL) in adult...
PenpulimabNot Annotated
Disitamab vedotinDisitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.
Retlirafusp alfaNot Annotated
NisevokitugNisevokitug is a monoclonal antibody targeted against transforming growth factor beta (TGFβ) under investigation in NCT04097821 (A Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel...
MarstacimabMarstacimab is a human Monoclonal Antibody Directed Against Tissue Factor Pathway Inhibitor currently being developed by Pfizer for the treatment of hemophilia A and hemophilia B.
NKTT-120NKTT-120 is a recombinant humanized IgG1k monoclonal antibody to human invariant T cell receptor (iTCR).
SevirumabNot Annotated
EdobacomabNot Annotated
PagibaximabNot Annotated
AVP-21D9AVP-21D9 is a fully human anthrax monoclonal antibody that is being investigated as an anthrax antitoxin.
UrtoxazumabNot Annotated
Hepatitis C immune globulin (human)Not Annotated
SenlizumabNot Annotated
BI-836858Not Annotated
DCLL-9718SDCLL9718S is an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1). DCLL9718S is under investigation in clinical trial NCT03298516 (A Study of DCLL9718S in Participants With Relapsed or Refractory Acute Myeloid...
XMMME-001-RTANot Annotated
XomaZyme-791Not Annotated
RespigamNot Available
QuisovalimabNot Annotated
MM-111MM-111 is a novel bispecific antibody fusion protein that co-targets the the epidermal growth factor family receptor tyrosine kinases, ERBB2 and ERBB3.
Tositumomab I-131Not Annotated
EDI-200EDI-200 is a fusion protein consisting of human immunoglobim G1 constant region Fc region fused to the human receptor binding domain of ectodysplasin-A1.
HemopexinNot Annotated
Anvatabart opadotinNot Annotated
MEDI-547MEDI-547 is an anti-EphA1 monoclonal antibody conjugated to mcMMAF
MDX-1097MDX-1097 is a chimeric monoclonal antibody directed against the kappa myeloma antigen (KMA).
ZilovertamabNot Annotated
CendakimabCendakimab is a recombinant humanized anti-interleukin 13 (IL-13) monoclonal antibody.
AVX-470AVX-470 is an anti-tumor necrosis factor (TNF) polyclonal antibody (bovine).
IMMU-114IMMU-114 is antibody-drug conjugate consisting of humanized anti-HLA-DR IgG4 monoclonal antibody specific for alpha-chain linked to SN-38 via a CL2A linker.
PemtumomabPemtumomab is a murine monoclonal antibody radiolabeled with Yttrium-90. It targets the mucin 1 (MUC1) protein.
LMB-100LMB-100 is a is an antibody-toxin conjugate with an antimesothelin Fab linked to a 24-kilodalton portion of Pseudomonas exotoxin A with mutations that decrease immunogenicity.
TimolumabTimolumab is a recombinant, fully-human, IgG4 immunoglobulin with antigen-binding specificity for human vascular adhesion protein-1 (VAP-1).
INH-A21INH-A21 is a human staphylococcal immunoglobulin
AcimtamigAcimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.
DilpacimabDilpacimab is under investigation in clinical trial NCT03368859 (A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and...
MelrilimabMelrilimab is under investigation in clinical trial NCT03207243 (Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma).
DonanemabDonanemab (LY3002813) is a humanized IgG1 monoclonal antibody targeted against an epitope at the N-terminal of a specific type of amyloid beta (Aβ) - pyroglutamate Aβ - which is found...
CalpurbatugCalpurbatug (TRL1068) is a high-affinity and broad-spectrum human antibody that targets and disintegrates bacterial biofilm.
RocatinlimabRocatinlimab is a subcutaneously administered anti-OX40 antibody developed for the treatment of moderate-to-severe atopic dermatitis. In clinical trials, it has shown significant efficacy and safety compared to a placebo. The...
ZiltivekimabZiltivekimab is under investigation in clinical trial NCT06200207 (A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation).
SonelokimabSonelokimab is under investigation in clinical trial NCT06411379 (Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa).
NofazinlimabNofazinlimab is under investigation in clinical trial NCT04194775 (A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma).
PlutavimabPlutavimab is under investigation in clinical trial NCT04900428 (Study to Evaluate a Single Intranasal Dose of STI-2099 (COVI-DROPS™) in Outpatient Adults With COVID-19 (UK)).
Farletuzumab ecteribulinFarletuzumab ecteribulin is under investigation in clinical trial NCT04300556 (A Study to Evaluate the Safety, Tolerability, and Efficacy of Morab-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha...
NetakimabNetakimab is under investigation in clinical trial NCT03447704 (International Multicenter Comparative Randomized Placebo-controlled Clinical Study of Efficacy and Safety of BCD-085 in Patients With Ankylosing Spondylitis).
ClesrovimabClesrovimab is under investigation in clinical trial NCT04938830 (Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)).
SemzuvolimabSemzuvolimab is under investigation in clinical trial NCT03149211 (To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults).
ErtumaxomabErtumaxomab is under investigation in clinical trial NCT00522457 (Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy).
IchorcumabIchorcumab is under investigation in clinical trial NCT03251482 (A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery).
MapatumumabMapatumumab is under investigation in clinical trial NCT00094848 (Study of TRM-1 (TRAIL-R1 Monoclonal Antibody) in Subjects With Relapsed or Refractory Non-hodgkin's Lymphoma (NHL)).
BeludavimabBeludavimab is under investigation in clinical trial NCT04746183 (AGILE (Early Phase Platform Trial for COVID-19)).
VeligrotugVeligrotug is under investigation in clinical trial NCT00791544 (Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma).
Troplasminogen alfaTroplasminogen alfa is under investigation in clinical trial NCT00144014 (Safety and Efficacy Study in Acute Ischaemic Stroke).
Drugs & Drug Targets
DrugTargetType
CetuximabEpidermal growth factor receptortarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CetuximabComplement C1q subcomponent subunit Atarget
CetuximabComplement C1q subcomponent subunit Btarget
CetuximabComplement C1q subcomponent subunit Ctarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor Itarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-atarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-btarget
Human immunoglobulin GLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Human immunoglobulin GHigh affinity immunoglobulin gamma Fc receptor IBtarget
Human immunoglobulin GComplement C3target
Human immunoglobulin GComplement C4-Atarget
Human immunoglobulin GComplement C4-Btarget
Human immunoglobulin GComplement C5target
OmalizumabImmunoglobulin heavy constant epsilontarget
AdalimumabTumor necrosis factortarget
InfliximabTumor necrosis factortarget
TrastuzumabReceptor tyrosine-protein kinase erbB-2target
RituximabB-lymphocyte antigen CD20target
BasiliximabInterleukin-2 receptor subunit alphatarget
BasiliximabInterleukin-2 receptor subunit betatarget
MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
MuromonabT-cell surface glycoprotein CD3 delta chaintarget
MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
TositumomabB-lymphocyte antigen CD20target
TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabCAMPATH-1 antigentarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
NatalizumabIntegrin alpha-4target
NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
NatalizumabIntercellular adhesion molecule 1target
PalivizumabFusion glycoprotein F0target
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
PalivizumabComplement C1r subcomponenttarget
PalivizumabComplement C1q subcomponent subunit Atarget
PalivizumabComplement C1q subcomponent subunit Btarget
PalivizumabComplement C1q subcomponent subunit Ctarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabVascular endothelial growth factor Atarget
BevacizumabComplement C1q subcomponent subunit Atarget
BevacizumabComplement C1q subcomponent subunit Btarget
BevacizumabComplement C1q subcomponent subunit Ctarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
EculizumabComplement C5target
PanitumumabEpidermal growth factor receptortarget
RamucirumabVascular endothelial growth factor receptor 2target
UstekinumabInterleukin-12 subunit betatarget
UstekinumabInterleukin-23target
LeronlimabC-C chemokine receptor type 5target
Caplacizumabvon Willebrand factortarget
CanakinumabInterleukin-1 betatarget
IpilimumabCytotoxic T-lymphocyte protein 4target
TocilizumabInterleukin-6 receptor subunit alphatarget
TocilizumabCytochrome P450 3A4enzyme
PertuzumabReceptor tyrosine-protein kinase erbB-2target
CatumaxomabEpithelial cell adhesion moleculetarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
MepolizumabInterleukin-5target
OfatumumabB-lymphocyte antigen CD20target
GolimumabTumor necrosis factortarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
NivolumabProgrammed cell death protein 1target
NivolumabProgrammed cell death 1 ligand 1target
DulaglutideGlucagon-like peptide 1 receptortarget
DaratumumabADP-ribosyl cyclase 1target
IxekizumabInterleukin-17Atarget
AtezolizumabProgrammed cell death 1 ligand 1target
AtezolizumabProgrammed cell death protein 1target
DurvalumabProgrammed cell death 1 ligand 1target
DurvalumabProgrammed cell death protein 1target
SarilumabCytochrome P450 3A4enzyme
SarilumabInterleukin-6 receptor subunit alphatarget
SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
GuselkumabInterleukin-23 subunit alphatarget
RomosozumabSclerostintarget
AvelumabProgrammed cell death 1 ligand 1target
AnifrolumabInterferon alpha/beta receptor 1target
OcrelizumabB-lymphocyte antigen CD20target
DupilumabInterleukin-4 receptor subunit alphatarget
DupilumabInterleukin-13target
DupilumabInterleukin-4target
TralokinumabInterleukin-13target
Polatuzumab vedotinCytochrome P450 3A4enzyme
Polatuzumab vedotinB-cell antigen receptor complex-associated protein beta chaintarget
Polatuzumab vedotinP-glycoprotein 1transporter
Polatuzumab vedotinCytochrome P450 3A5enzyme
AducanumabAmyloid beta A4 proteintarget
MogamulizumabC-C chemokine receptor type 4target
InebilizumabB-lymphocyte antigen CD19target
IbalizumabT-cell surface glycoprotein CD4target
IbalizumabC-C chemokine receptor type 5target
IbalizumabC-X-C chemokine receptor type 4target
Sacituzumab govitecanTumor-associated calcium signal transducer 2target
Sacituzumab govitecanDNA topoisomerase 1target
Sacituzumab govitecanFar upstream element-binding protein 1target
Sacituzumab govitecanUDP-glucuronosyltransferase 1-1enzyme
OlokizumabInterleukin-6target
EmicizumabCoagulation factor IXtarget
EmicizumabCoagulation factor Xtarget
TildrakizumabInterleukin-23target
TildrakizumabCytochrome P450 4A11enzyme
FremanezumabCalcitonin gene-related peptide 1target
FremanezumabCalcitonin gene-related peptide 2target
LanadelumabPlasma kallikreintarget
EmapalumabInterferon gammatarget
RisankizumabInterleukin-23target
IsatuximabADP-ribosyl cyclase 1target
EptinezumabCalcitonin gene-related peptide 1target
EptinezumabCalcitonin gene-related peptide 2target
GalcanezumabCalcitonin gene-related peptide 1target
GalcanezumabCalcitonin gene-related peptide 2target
CemiplimabProgrammed cell death protein 1target
BrolucizumabVascular endothelial growth factor Atarget
Trastuzumab deruxtecanP-glycoprotein 1transporter
Trastuzumab deruxtecanHigh affinity immunoglobulin gamma Fc receptor Itarget
Trastuzumab deruxtecanDNA topoisomerase 1target
Trastuzumab deruxtecanLysosomal alpha-glucosidaseenzyme
Trastuzumab deruxtecanDNA topoisomerase 1enzyme
Trastuzumab deruxtecanCathepsin Benzyme
Trastuzumab deruxtecanCathepsin L1enzyme
Trastuzumab deruxtecanCytochrome P450 3A4enzyme
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B1transporter
Trastuzumab deruxtecanSolute carrier organic anion transporter family member 1B3transporter
Trastuzumab deruxtecanMultidrug and toxin extrusion protein 2transporter
Trastuzumab deruxtecanMultidrug resistance-associated protein 1transporter
Trastuzumab deruxtecanATP-binding cassette sub-family G member 2transporter
MargetuximabReceptor tyrosine-protein kinase erbB-2target
TafasitamabB-lymphocyte antigen CD19target
TezepelumabThymic stromal lymphopoietintarget
EvinacumabAngiopoietin-related protein 3target
TeprotumumabInsulin-like growth factor 1 receptortarget
Belantamab mafodotinSolute carrier organic anion transporter family member 1B1transporter
Belantamab mafodotinSolute carrier organic anion transporter family member 1B3transporter
Belantamab mafodotinMultidrug resistance-associated protein 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 1transporter
Belantamab mafodotinCanalicular multispecific organic anion transporter 2transporter
Belantamab mafodotinBile salt export pumptransporter
Belantamab mafodotinP-glycoprotein 1transporter
Belantamab mafodotinTumor necrosis factor receptor superfamily member 17target
AmivantamabEpidermal growth factor receptortarget
AmivantamabHepatocyte growth factor receptortarget
AmivantamabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
PlasminogenTissue-type plasminogen activatorenzyme
PlasminogenUrokinase-type plasminogen activatorenzyme
Alpha-1-proteinase inhibitorNeutrophil elastasetarget
Hepatitis B immune globulinHBsAgtarget
EflapegrastimGranulocyte colony-stimulating factor receptortarget
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
AbciximabVitronectintarget
Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
Ibritumomab tiuxetanB-lymphocyte antigen CD20target
Capromab pendetideGlutamate carboxypeptidase 2target
AlefaceptT-cell surface antigen CD2target
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
EfalizumabIntegrin alpha-Ltarget
EfalizumabIntegrin alpha-Xtarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DaclizumabInterleukin-2 receptor subunit alphatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DaclizumabComplement C1r subcomponenttarget
DaclizumabComplement C1q subcomponent subunit Atarget
DaclizumabComplement C1q subcomponent subunit Btarget
DaclizumabComplement C1q subcomponent subunit Ctarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DaclizumabInterleukin-2 receptor subunit betatarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
RanibizumabVascular endothelial growth factor Atarget
AbataceptT-lymphocyte activation antigen CD80target
AbataceptT-lymphocyte activation antigen CD86target
AbataceptCytotoxic T-lymphocyte protein 4target
GaliximabT-lymphocyte activation antigen CD80target
AfelimomabTumor necrosis factortarget
EpratuzumabB-cell receptor CD22target
OregovomabMucin-16target
IGN311Epidermal growth factor receptortarget
IGN311Receptor tyrosine-protein kinase erbB-2target
LabetuzumabCarcinoembryonic antigen-related cell adhesion molecule 5target
MatuzumabEpidermal growth factor receptortarget
FontolizumabInterferon gammatarget
CR002Platelet-derived growth factor Dtarget
RozrolimupabRhesus blood group D antigentarget
GirentuximabCarbonic anhydrase 9target
GirentuximabInterleukin-2target
BriakinumabInterleukin-12 subunit betatarget
BriakinumabInterleukin-23 subunit alphatarget
IratumumabTumor necrosis factor receptor superfamily member 8target
FarletuzumabFolate receptor alphatarget
Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
Trastuzumab emtansineP-glycoprotein 1transporter
Trastuzumab emtansineCytochrome P450 3A4enzyme
Trastuzumab emtansineCytochrome P450 3A5enzyme
PRO-542Free fatty acid receptor 4target
TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
Inotuzumab ozogamicinP-glycoprotein 1transporter
Inotuzumab ozogamicinB-cell receptor CD22target
RI 624Beta-nerve growth factortarget
StamulumabGrowth/differentiation factor 8target
CT-011Programmed cell death protein 1target
PegdinetanibVascular endothelial growth factor receptor 2target
MK-4721Prostate stem cell antigentarget
Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
OlaratumabPlatelet-derived growth factor receptor alphatarget
TB-402Coagulation factor VIIItarget
IMC-1C11Vascular endothelial growth factor receptor 1target
IMC-1C11Vascular endothelial growth factor receptor 2target
IMC-1C11Vascular endothelial growth factor receptor 3target
EldelumabC-X-C motif chemokine 10target
LumiliximabLow affinity immunoglobulin epsilon Fc receptortarget
ClenoliximabT-cell surface glycoprotein CD4target
ElotuzumabSLAM family member 7target
AVE9633Myeloid cell surface antigen CD33target
AVE9633Cytochrome P450 3A4enzyme
CarotuximabEndoglintarget
XmAb 2513Tumor necrosis factor receptor superfamily member 8target
Coltuximab ravtansineB-lymphocyte antigen CD19target
Coltuximab ravtansineCytochrome P450 3A4enzyme
LucatumumabTumor necrosis factor receptor superfamily member 5target
SiplizumabT-cell surface antigen CD2target
SibrotuzumabSeprasetarget
AtibuclimabMonocyte differentiation antigen CD14target
BivatuzumabCD44 antigentarget
LexatumumabTumor necrosis factor receptor superfamily member 10Btarget
ReslizumabInterleukin-5target
TeplizumabT-cell surface glycoprotein CD3 epsilon chaintarget
DenosumabTumor necrosis factor ligand superfamily member 11target
BelataceptT-lymphocyte activation antigen CD86target
BelataceptT-lymphocyte activation antigen CD80target
Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
Brentuximab vedotinCytochrome P450 3A4enzyme
Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
BelimumabTumor necrosis factor ligand superfamily member 13Btarget
RaxibacumabProtective antigentarget
ObinutuzumabB-lymphocyte antigen CD20target
SecukinumabInterleukin-17Atarget
VedolizumabIntegrin alpha-4target
VedolizumabIntegrin beta-7target
SiltuximabInterleukin-6target
SiltuximabCytochrome P450 3A4enzyme
PembrolizumabProgrammed cell death protein 1target
PembrolizumabProgrammed cell death 1 ligand 1target
BlinatumomabB-lymphocyte antigen CD19target
BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DinutuximabGD2 disialogangliosidetarget
Asfotase alfaPyrophosphatetarget
AlirocumabProprotein convertase subtilisin/kexin type 9target
EvolocumabProprotein convertase subtilisin/kexin type 9target
Technetium Tc-99m nofetumomab merpentanEpithelial cell adhesion moleculetarget
Technetium Tc-99m nofetumomab merpentanB-lymphocyte antigen CD20target
NecitumumabEpidermal growth factor receptortarget
RavulizumabComplement C5target
Antithrombin III humanAntithrombin-IIItarget
Depatuxizumab mafodotinEpidermal growth factor receptortarget
Depatuxizumab mafodotinTubulin beta chaintarget
Depatuxizumab mafodotinB-lymphocyte antigen CD19target
TremelimumabCytotoxic T-lymphocyte protein 4target
DalotuzumabInsulin-like growth factor 1 receptortarget
UblituximabB-lymphocyte antigen CD20target
LebrikizumabInterleukin-13target
UlocuplumabC-X-C chemokine receptor type 4target
BenralizumabInterleukin-5 receptor subunit alphatarget
BenralizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
GantenerumabAmyloid beta A4 proteintarget
UrelumabTumor necrosis factor receptor superfamily member 9target
Lorvotuzumab mertansineCytochrome P450 3A4enzyme
GevokizumabInterleukin-1 betatarget
FasinumabBeta-nerve growth factortarget
EtrolizumabIntegrin beta-7target
ZalutumumabEpidermal growth factor receptortarget
CixutumumabInsulin-like growth factor 1 receptortarget
VanucizumabAngiopoietin-2target
VanucizumabVascular endothelial growth factor Atarget
Mirvetuximab soravtansineCytochrome P450 3A4enzyme
Mirvetuximab soravtansineFolate receptor alphatarget
Mirvetuximab soravtansineP-glycoprotein 1transporter
PlozalizumabC-C chemokine receptor type 2target
DacetuzumabTumor necrosis factor receptor superfamily member 5target
Moxetumomab pasudotoxB-cell receptor CD22target
Moxetumomab pasudotoxElongation factor 2target
SifalimumabInterferon alpha-2target
AmatuximabMesothelintarget
BimekizumabInterleukin-17Atarget
BimekizumabInterleukin-17Ftarget
Enfortumab vedotinCytochrome P450 3A4enzyme
Enfortumab vedotinNectin-4target
Enfortumab vedotinP-glycoprotein 1transporter
BezlotoxumabClostridium difficile Toxin Btarget
BesilesomabCarcinoembryonic antigentarget
BurosumabFibroblast growth factor 23target
ErenumabCalcitonin gene-related peptide type 1 receptortarget
LecanemabAmyloid beta A4 proteintarget
CamrelizumabProgrammed cell death protein 1target
CamrelizumabProgrammed cell death 1 ligand 1target
SpartalizumabProgrammed cell death protein 1target
MirikizumabInterleukin-23 subunit alphatarget
RozanolixizumabIgG receptor FcRn large subunit p51target
TislelizumabProgrammed cell death protein 1target
SutimlimabComplement C1s subcomponenttarget
ToripalimabProgrammed cell death protein 1target
Efgartigimod alfaIgG receptor FcRn large subunit p51target
CrizanlizumabP-selectintarget
SpesolimabInterleukin-1 receptor-like 2target
DostarlimabProgrammed cell death protein 1target
InolimomabInterleukin-2 receptor subunit alphatarget
Anti-SARS-CoV-2 REGN-COV2Spike glycoproteintarget
BamlanivimabSpike glycoproteintarget
SatralizumabInterleukin-6 receptor subunit alphatarget
SintilimabProgrammed cell death protein 1target
EnvafolimabProgrammed cell death 1 ligand 1target
EtesevimabSpike glycoproteintarget
AtoltivimabEnvelope glycoproteintarget
MaftivimabEnvelope glycoproteintarget
OdesivimabEnvelope glycoproteintarget
ImdevimabSpike glycoproteintarget
CasirivimabSpike glycoproteintarget
NaxitamabGD2 disialogangliosidetarget
Loncastuximab tesirineB-lymphocyte antigen CD19target
Loncastuximab tesirineP-glycoprotein 1transporter
Loncastuximab tesirineCytochrome P450 3A4enzyme
Loncastuximab tesirineCytochrome P450 3A5enzyme
NirsevimabFusion glycoprotein F0target
NirsevimabFusion glycoprotein F0target
NirsevimabFusion glycoprotein F0target
OlinvacimabVascular endothelial growth factor receptor 2target
OtlertuzumabLeukocyte antigen CD37target
SotrovimabSpike glycoproteintarget
GlofitamabB-lymphocyte antigen CD20target
GlofitamabT-cell surface glycoprotein CD3target
AnsuvimabEnvelope glycoproteintarget
CilgavimabSpike glycoproteintarget
TixagevimabSpike glycoproteintarget
RegdanvimabSpike glycoproteintarget
VilobelimabComplement C5target
NarsoplimabMannan-binding lectin serine protease 2target
BudigalimabProgrammed cell death protein 1target
Tisotumab vedotinCytochrome P450 3A4enzyme
Tisotumab vedotinTissue factortarget
Tisotumab vedotinP-glycoprotein 1transporter
BebtelovimabSpike glycoproteintarget
RelatlimabLymphocyte activation gene 3 proteintarget
FaricimabVascular endothelial growth factor Atarget
FaricimabAngiopoietin-2target
RocatinlimabTumor necrosis factor receptor superfamily member 4target